EA201892796A1 - Связывающиеся с сывороточным альбумином домены фибронектина типа iii - Google Patents

Связывающиеся с сывороточным альбумином домены фибронектина типа iii

Info

Publication number
EA201892796A1
EA201892796A1 EA201892796A EA201892796A EA201892796A1 EA 201892796 A1 EA201892796 A1 EA 201892796A1 EA 201892796 A EA201892796 A EA 201892796A EA 201892796 A EA201892796 A EA 201892796A EA 201892796 A1 EA201892796 A1 EA 201892796A1
Authority
EA
Eurasian Patent Office
Prior art keywords
domains
serum albumin
type iii
fibronectin type
albumin domains
Prior art date
Application number
EA201892796A
Other languages
English (en)
Inventor
Майкл Дим
Стивен ДЖЕКОБС
Карин О'Нил
Томас Руткоски
Original Assignee
Янссен Байотек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Байотек, Инк. filed Critical Янссен Байотек, Инк.
Publication of EA201892796A1 publication Critical patent/EA201892796A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/76—Assays involving albumins other than in routine use for blocking surfaces or for anchoring haptens during immunisation
    • G01N2333/765—Serum albumin, e.g. HSA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]

Abstract

Домены фибронектина типа III (FN3), которые специфически связываются с сывороточным альбумином, имеющие к ним отношение полинуклеотиды, способные кодировать специфические в отношении сывороточного альбумина домены FN3, клетки, экспрессирующие домены FN3, а также ассоциированные векторы, помеченные детектируемым образом домены FN3 и домены FN3, слитые с гетерологичной составляющей, полезны для продления периода полужизни молекул при диагностических и терапевтических применениях.
EA201892796A 2016-06-03 2017-06-01 Связывающиеся с сывороточным альбумином домены фибронектина типа iii EA201892796A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662345190P 2016-06-03 2016-06-03
PCT/US2017/035442 WO2017210425A1 (en) 2016-06-03 2017-06-01 Serum albumin-binding fibronectin type iii domains

Publications (1)

Publication Number Publication Date
EA201892796A1 true EA201892796A1 (ru) 2019-06-28

Family

ID=60477987

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892796A EA201892796A1 (ru) 2016-06-03 2017-06-01 Связывающиеся с сывороточным альбумином домены фибронектина типа iii

Country Status (13)

Country Link
US (3) US10925932B2 (ru)
EP (1) EP3463430A4 (ru)
JP (2) JP7111627B2 (ru)
KR (1) KR102461666B1 (ru)
CN (1) CN109562146A (ru)
AU (1) AU2017273743B2 (ru)
EA (1) EA201892796A1 (ru)
IL (2) IL263347B (ru)
MA (1) MA45186A (ru)
MX (1) MX2018014876A (ru)
SG (1) SG11201810687SA (ru)
UA (1) UA126021C2 (ru)
WO (1) WO2017210425A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016008125B1 (pt) 2013-10-14 2023-11-21 Janssen Biotech, Inc. Domínio proteico isolado de fibronectina tipo iii modificado com cisteína, seu método de produção e método para produzir uma molécula isolada de de fibronectina tipo iii biespecífica modificada com cisteína
WO2017210425A1 (en) * 2016-06-03 2017-12-07 Janssen Biotech, Inc. Serum albumin-binding fibronectin type iii domains
CN109689080A (zh) * 2016-06-21 2019-04-26 詹森生物科技公司 半胱氨酸工程化iii型纤连蛋白结构域结合分子
US10597438B2 (en) 2016-12-14 2020-03-24 Janssen Biotech, Inc. PD-L1 binding fibronectin type III domains
US10611823B2 (en) 2016-12-14 2020-04-07 Hanssen Biotech, Inc CD137 binding fibronectin type III domains
AU2017378226A1 (en) 2016-12-14 2019-06-20 Janssen Biotech, Inc. CD8A-binding fibronectin type III domains
CN110724198B (zh) * 2018-07-17 2023-05-26 上海一宸医药科技有限公司 长效纤连蛋白iii型结构域融合蛋白
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
CN114786682A (zh) 2019-10-14 2022-07-22 Aro生物疗法公司 结合cd71的纤维粘连蛋白iii型结构域
USD1021702S1 (en) * 2021-10-20 2024-04-09 GM Global Technology Operations LLC Vehicle center grille

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0494955B1 (en) 1989-10-05 1998-07-15 Optein, Inc. Cell-free synthesis and isolation of novel genes and polypeptides
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
DK0669836T3 (da) 1992-11-13 1996-10-14 Idec Pharma Corp Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
DE69839147T2 (de) 1997-06-12 2009-02-19 Novartis International Pharmaceutical Ltd. Künstliche antikörperpolypeptide
ES2278463T3 (es) 1998-12-08 2007-08-01 Biovation Limited Metodo para reducir la inmunogenicidad de proteinas.
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
ATE422369T1 (de) 1999-12-24 2009-02-15 Genentech Inc Verfahren und zusammensetzungen zur verlängerung der entsorgungshalbwertszeit von biowirksamen verbindungen
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20130226834A1 (en) 2000-04-27 2013-08-29 Networth Services, Inc. Systems and methods for determining the financial status of bonds
JP4602614B2 (ja) 2001-09-26 2010-12-22 アイシン精機株式会社 自動車用ドア
JP2006512895A (ja) 2002-06-28 2006-04-20 ドマンティス リミテッド リガンド
DE60335000D1 (de) 2002-09-06 2010-12-30 Isogenica Ltd In vitro peptid-expressionsbank
WO2009085462A1 (en) 2007-12-19 2009-07-09 Centocor, Inc. Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
EP2231870A4 (en) 2007-12-19 2011-01-26 Centocor Ortho Biotech Inc SYNTHESIS PHAGE VECTORS FOR DESIGNING AND GENERATING A BANK OF PROTEIN PHAGES OR PEPTIDES HUMAN NON-ANTIBODIES BY MELTING AT PIX OF PHAGE M13
CA3149920A1 (en) * 2008-10-31 2010-05-06 Janssen Biotech, Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
RU2562700C2 (ru) * 2009-02-12 2015-09-10 Янссен Байотек, Инк. Композиции, способы получения и применение каркаса на основе домена фибронектина типа iii
PT3103478T (pt) 2010-04-30 2019-07-10 Janssen Biotech Inc Composições, métodos e utilizações de domínios de fibronectinas estabilizadas
TW201138808A (en) * 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
ES2573108T3 (es) * 2010-05-26 2016-06-06 Bristol-Myers Squibb Company Proteínas de armazón a base de fibronectina que tienen estabilidad mejorada
WO2013049275A1 (en) * 2011-09-27 2013-04-04 Janssen Biotech, Inc. Fibronectin type iii repeat based protein scaffolds with alternative binding surfaces
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
CA2932819A1 (en) * 2013-12-09 2015-06-18 New York University Compositions and methods for phagocyte delivery of anti-staphylococcal agents
SG11201607820QA (en) * 2014-03-20 2016-10-28 Bristol Myers Squibb Co Serum albumin-binding fibronectin type iii domains
JP2018517708A (ja) * 2015-06-05 2018-07-05 ニューヨーク・ユニバーシティ 抗ブドウ球菌生物学的薬剤のための組成物及び方法
WO2017210425A1 (en) * 2016-06-03 2017-12-07 Janssen Biotech, Inc. Serum albumin-binding fibronectin type iii domains
CN109689080A (zh) * 2016-06-21 2019-04-26 詹森生物科技公司 半胱氨酸工程化iii型纤连蛋白结构域结合分子

Also Published As

Publication number Publication date
CN109562146A (zh) 2019-04-02
KR102461666B1 (ko) 2022-11-01
IL263347B (en) 2021-05-31
EP3463430A4 (en) 2020-02-12
MX2018014876A (es) 2019-05-22
US10925932B2 (en) 2021-02-23
UA126021C2 (uk) 2022-08-03
US20240100129A1 (en) 2024-03-28
US20170348397A1 (en) 2017-12-07
US11833190B2 (en) 2023-12-05
MA45186A (fr) 2019-04-10
EP3463430A1 (en) 2019-04-10
AU2017273743B2 (en) 2021-12-02
US20210228688A1 (en) 2021-07-29
IL282960A (en) 2021-06-30
JP7111627B2 (ja) 2022-08-02
WO2017210425A1 (en) 2017-12-07
AU2017273743A1 (en) 2019-01-03
JP2019521662A (ja) 2019-08-08
JP2022046510A (ja) 2022-03-23
SG11201810687SA (en) 2018-12-28
IL282960B (en) 2022-03-01
IL263347A (en) 2018-12-31
KR20190013970A (ko) 2019-02-11

Similar Documents

Publication Publication Date Title
EA201892796A1 (ru) Связывающиеся с сывороточным альбумином домены фибронектина типа iii
EA202090216A2 (ru) Связывающие сывороточный альбумин домены фибронектина iii типа
UY37340A (es) Antianticuerpos gprc5d, moléculas de unión al antígeno biespecíficas que se unen a gprc5d y cd3, y usos de estas
CO6630173A2 (es) Moléculas de unión a seroalbuminae
AR106555A1 (es) Anticuerpos anti-il1rap, moléculas de unión a antígenos biespecíficas que se unen a il1rap y cd3, y usos de estas
CO2019000931A2 (es) Polipéptidos modificados y usos de los mismos
CL2019001000A1 (es) Proteínas de fusión fc heterodiméricas il15/il15ralfa
MX2023003630A (es) Aglutinantes de albumina de suero mejorados.
CL2012001258A1 (es) Un polipeptido de factor de von willebrand (fvw) aislado que comprende un dominio de union a factor viii (fviii), donde dicho polipeptido carece de algunos dominios del fvw, comprende una secuencia de aminoacidos de fc de inmunoglobulina; composicion y complejo proteico que lo comprende; celula que expresa dicho polipeptido; celula que expresa dicho complejo proteico; composición que comprende el complejo proteico.
MX2020011788A (es) Acoplador trifuncional de antigeno de celulas t y metodos y usos del mismo.
AR095596A1 (es) Moléculas de unión de cadena única comprendiendo n-terminal abp
DOP2019000011A (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123
MX353382B (es) Moleculas de union polipeptido de larga duracion.
UY36859A (es) Anticuerpos anti-bcma, moléculas de unión a antígenos biespecíficas que se unen a bcma y cd3, y usos de estas
WO2017053619A8 (en) Glypican-3binding fibronectin based scafflold molecules
ECSP13013102A (es) Dominios no inmunizados que se unen al suero y su uso para extender la vida media en el suero
EA201990017A1 (ru) Антитела к миостатину и способы их применения
EA201792441A2 (ru) Домены фибронектина типа iii, связывающиеся с простатспецифическим мембранным антигеном
GB2549632A (en) Fusion protein comprising three binding domains to 5TA and CD3
EA201491524A1 (ru) Связывающиеся с эритроцитами терапевтические средства
EA201792442A1 (ru) Биспецифические агенты, связывающие простатический специфический мембранный антиген (psma), и их применение
EA201690773A1 (ru) Связующие молекулы на основе домена фибронектина типа iii с внедренными остатками цистеина
EA201491494A1 (ru) Нацеливание на гликаны хондроитинсульфаты
EA201990067A1 (ru) Цистеин-модифицированные связывающие молекулы на основе домена фибронектина iii типа
BR112019012154A2 (pt) domínios do tipo iii da fibronectina de ligação a cd8a